Academic Journals Database
Disseminating quality controlled scientific knowledge

L-dopa-Induced Dyskinesias in Parkinson’s Disease

Author(s): Iciar Aviles-Olmos | Raul Martinez-Fernandez | Thomas Foltynie

Journal: European Neurological Journal
ISSN 2041-8000

Volume: 2;
Issue: 2;
Start page: 91;
Date: 2010;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: levodopa-induced dyskinesia (LID) | Parkinson’s disease (PD) | synaptic plasticity | dysfunctional dopamine release | dopamine receptor supersensitivity

Levodopa (L-dopa) is the most effective treatment for the relief of the motor symptoms of Parkinson’s disease (PD). Its use is limited by the development of drug-induced involuntary movements known as dyskinesias, which can appear in approximately 40% of the PD patients after 5 years of treatment. In recent years we have learned a great deal about the processes involved in the appearance of L-dopa-induced dyskinesia (LID). Non-physiological pulsatile stimulation of dopamine receptors that occurs as a consequence of the use of short-lasting drugs, dysfunctional dopamine release, and abnormal postsynaptic dopamine receptor internalization together with disrupted synaptic plasticity all appear to have direct effects on LID development. Avoiding or delaying dyskinesia development and treating patients in this “advanced” stage of PD is a challenge and requires considerable expertise and individualization of therapy. The aim of this review is to outline the clinical phenomenology of LID, describe an overview of what is known about their pathophysiology, and provide guidance in the range of therapeutic approaches that can be tailored to the individual patient.
RPA Switzerland

RPA Switzerland

Robotic process automation


Tango Jona
Tangokurs Rapperswil-Jona